Evolus Raises 2026 Outlook After Q2 Revenue Jumps 21%
EOLS sits 73% above its 52-week low of $3.86.
Summary
Evolus posted Q2 revenue of $83.35M, up 21% year-over-year, driven by double-digit growth in Jeuveau and increased adoption of Evolysse. The company delivered its third straight quarter of positive adjusted EBITDA, reflecting improved operating leverage. Management raised full-year 2026 revenue guidance to $330M-$337M (from $327M-$337M) and lifted adjusted gross margin outlook to 67.0%-67.5% (from 65.5%-67.0%), while reaffirming low- to mid-single digit adjusted EBITDA margin. This follows the recent expansion of the Symatese partnership for Estyme HA gels and the IBSA licensing deal for Profhilo, broadening the international portfolio. The raised guidance and margin expansion signal accelerating commercial momentum and profitability. With shares at $6.67 and a $407M market cap, the improved outlook and pipeline progress strengthen the investment case.
At the time of this announcement, EOLS was trading at $6.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $407M. The 52-week trading range was $3.86 to $9.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.